Use of pyrazolopyrimidine derivatives in treating diabetic nephropathy

A technology for diabetic nephropathy and pyrazolopyrimidine, which is applied in the fields of urinary system diseases, medical preparations containing active ingredients, metabolic diseases, etc., can solve problems such as no diabetic nephropathy application, and achieve expansion of drug selectivity and application Range, effect of multiple drug options

Active Publication Date: 2021-07-30
GUANGXI WUZHOU PHARMA GRP
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there are only reports about pyrazolopyrimidine derivatives in the treatment of acute myeloid leukemia and psoriasis, but no use in the treatment of diabetic nephropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of pyrazolopyrimidine derivatives in treating diabetic nephropathy
  • Use of pyrazolopyrimidine derivatives in treating diabetic nephropathy
  • Use of pyrazolopyrimidine derivatives in treating diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Effect of Example 1 on Diabetic Nephropathy Rats

[0035] 1. Experimental animals: clean-grade SD rats, male, weighing 200-220 g, were purchased from Shanghai Slack Experimental Animal Co., Ltd.

[0036] 2. Experimental materials: pyrazolopyrimidine derivatives were synthesized by the inventors. Mix castor oil and ethanol 1:1 and pass through a 0.22 μm sterile filter membrane to obtain ELE solution, weigh a certain amount of pyrazolopyrimidine derivative powder of the present invention, dissolve the powder with ELE solution, and after the powder is completely dissolved, Add a certain volume of sterilized water, mix well and set aside. The volume ratio of ELE solution to sterile water is 1:3. High-sugar and high-fat feed (formula: basic feed: egg yolk: lard: sodium cholate: sucrose=63.5:10:8:0.5:18).

[0037] 3. Establishment of the animal model: After the rats were adaptively fed for 1 week, the urine of the rats was collected in a metabolic cage to measure the urine...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicines, in particular to the use of pyrazolopyrimidine derivatives in treating diabetic nephropathy. The pyrazolopyrimidine derivatives of the present invention have a good therapeutic effect on diabetic nephropathy, can significantly reduce the amount of urinary protein excretion in rats with diabetic nephropathy, significantly reduce the content of urea nitrogen, creatinine, and IL-6 in serum, and can also significantly inhibit the kidney disease. Expression levels of MCP‑1 and TGF‑β1 in tissues.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to the use of pyrazolopyrimidine derivatives in treating diabetic nephropathy. Background technique [0002] Diabetic nephropathy is one of the most common and serious chronic complications of diabetes. Current studies have found that the pathogenesis of diabetic nephropathy is complex, in which inflammatory response is a key factor in the occurrence and development of diabetic nephropathy, mainly involving interleukin 6 (IL-6), transforming growth factor β1 (TGF-β1), monocyte chemotaxis Protein 1 (MCP-1), etc., they play different mechanisms of action. [0003] The pyrazolopyrimidine derivative (Formula I) is a small-molecule inhibitor targeting FLT3 kinase. It is a new type of compound independently developed by the applicant. At present, the compound patent has been authorized in China, the United States, Japan and other regions. [0004] At present, there are only reports ab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/519A61P13/12A61P3/10
CPCA61K31/519A61P3/10A61P13/12
Inventor 陈焕展欧阳静波李柏霖卢蕾羽李鑫吴水华韦杰
Owner GUANGXI WUZHOU PHARMA GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap